Accessibility Menu
eXoZymes logo

eXoZymes(NASDAQ) EXOZ

Market Cap$64.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2024)-20%
5 YearN/A
1 Year-25%
1 Month+48%
$7.80
+12.23%
+0.85Today
eXoZymes last closing stock price
MetricPriceDate
Last closeUSD 6.952026-08-24
eXoZymes stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+15.26%USD 6.032026-08-17
1 month+47.56%USD 4.712026-07-24
3 month-29.87%USD 9.912026-05-26
Year to date-36.24%USD 10.902025-12-31
1 year-25.35%USD 9.312025-08-22
Since inception-19.65%USD 8.652024-11-13

eXoZymes Financials at a Glance

Market Cap

$64.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$10.19M

EPS (TTM)

-$1.20

P/E Ratio

-5.78

Dividend

$0.00

Beta (Volatility)

0.59 (Low)

Price

$7.80

Volume

2,675.129

Open

$7.18

Previous Close

$6.95

Daily Range

$6.45 - $7.80

52-Week Range

$4.35 - $18.40

Estimated Earnings Date

Mar 31, 2026

EXOZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About eXoZymes

eXoZymes creates enzyme-based systems that help make chemicals without using living cells. Its technology supports industries like pharmaceuticals and fuels by offering new ways to produce essential compounds. The company’s solutions aim to simplify manufacturing for partners in health, energy, and materials.

Mixing It Up: Products and Services

  • SimplePath platform: Cell-free system for making chemicals, targeting pharmaceutical and nutraceutical companies (0% of revenue in 2025).
  • Exozyme biosolutions: Modular enzyme kits for specific chemical conversions, used by research and manufacturing partners (0% of revenue in 2025).
  • NCT program: Produces a small molecule for metabolic health, aimed at supplement and drug developers (0% of revenue in 2025).
  • Isobutanol project: Makes isobutanol for sustainable aviation fuel and industrial chemicals, serving energy and chemical sectors (0% of revenue in 2025).
  • Licensing and partnerships: Offers technology access and support to other companies, with no commercial sales as of 2025.

Scaling Up: Growth and Expansion Moves

  • Launched the NCT program in 2025, transferring technology to an external pilot plant.
  • Formed the NCTX subsidiary in 2025 to commercialize NCT using contract manufacturing.
  • Secured an approximately $1M grant from the Department of Defense BioMADE initiative in October 2024 for isobutanol development.
  • Received a $3M National Science Foundation subaward via Georgia Tech in July 2025 for scaling cell-free systems.
  • Expanded R&D and pilot production space to 10,000 sq. ft. in Monrovia, California in 2025.

Why eXoZymes Catches the Eye

eXoZymes uses cell-free enzyme systems, avoiding the limits of living cell production. Its modular approach allows quick adaptation for new chemical targets. The company relies on partnerships and licensing, not direct manufacturing, to reach markets.

Five Things You Need to Know

  • Revenue was $0 in 2025, unchanged from 2024 and 2023.
  • Operating loss was $9.7 million in 2025, up 63.8% from 2024.
  • Cash and equivalents were $3.04 million at December 31, 2025, down 68.7% year-over-year.
  • R&D costs rose 98.4% to $3.7 million in 2025.
  • All funding comes from grants and equity, with no product sales as of 2025.

Bottom Line

eXoZymes has built a flexible enzyme platform and focuses on partnerships, not direct sales. The company remains pre-revenue, relying on grants and investment to fund its growth.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

32

CEO

Michael Heltzen

Website

exozymes.com

Headquarters

Monrovia, CA 91016, US

EXOZ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-292.13%

Return on Capital

-209.38%

Return on Assets

-127.67%

Earnings Yield

-17.30%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$64.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

9.28M

Volume

2.68K

Avg. Volume

9.46K

Financials (TTM)

Gross Profit

$68.61K

Operating Income

-$10.56M

EBITDA

-$10.58M

Operating Cash Flow

-$7.00M

Capital Expenditure

-$145.90K

Free Cash Flow

-$7.14M

Cash & ST Invst.

$5.65M

Total Debt

$1.09M

eXoZymes Performance Analysis

eXoZymes annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 70,069N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
eXoZymes sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
Q22026-06-30N/A
eXoZymes annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -0.120.3%
20232023-12-31USD -0.24108.2%
20242024-12-31USD -0.70187.6%
20252025-12-31USD -1.0956.0%
eXoZymes sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-303.6%
Q42025-12-31-18.5%
Q12026-03-3112.5%
Q22026-06-30-17.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$0.00

+100.0%

Gross Margin

0.00%

N/A

Market Cap

$64.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$2.02M

N/A

Employees

32

N/A

Net Income

-$2.88M

-22.0%

EBITDA

-$3.03M

-32.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$5.65M

-19.1%

Total Debt

$1.09M

-22.2%

Accounts Receivable

$219.87K

-14.7%

Inventory

$0.00

N/A

Long Term Debt

$741.31K

-33.1%

Short Term Debt

$343.73K

+20.1%

Return on Assets

-1.28%

N/A

Return on Invested Capital

-1.66%

N/A

Free Cash Flow

-$1.64M

-3.3%

Operating Cash Flow

-$1.64M

-6.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TLSATiziana Life Sciences Ltd
$1.11-3.48%
TILInstil Bio, Inc.
$7.80-0.13%
ONCYOncolytics Biotech Inc.
$0.87+3.02%
CGTXCognition Therapeutics, Inc.
$1.03+4.11%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$212.99+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.24+0.02%
BITOProShares Trust - ProShares Bitcoin ETF
$10.68+0.00%
INTCIntel
$87.76+0.01%

Questions About EXOZ

What is the current price of eXoZymes?

eXoZymes is trading at $7.80 per share.

What is the 52-week range for eXoZymes?

Over the past 52 weeks, eXoZymes has traded between $4.35 and $18.40.

How much debt does eXoZymes have?

As of the most recent reporting period, eXoZymes reported total debt of $1.09M.

How much cash does eXoZymes have on hand?

eXoZymes reported $5.65M in cash and cash equivalents in its most recent financial results.

What is eXoZymes’s dividend yield?

eXoZymes does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services